Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Biopharmaceutical Excipients Market Size

ID: MRFR/HC/9128-HCR
200 Pages
Rahul Gotadki
April 2026

Biopharmaceutical Excipients Market Research Report By Application (Injectable Formulations, Oral Formulations, Topical Formulations, Transdermal Formulations, Cell and Gene Therapy), By Type (Binders, Disintegrants, Lubricants, Preservatives, Stabilizers), By Functionality (Functional Excipients, Multi-functional Excipients, Inert Excipients, Active Excipients), By End-use (Pharmaceutical Companies, Contract Manufacturing Organizations, Research Institutes), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Biopharmaceutical Excipients Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Biopharmaceutical Excipients Size

Biopharmaceutical Excipients Market Growth Projections and Opportunities

The biopharmaceutical excipients market encompasses various ingredients used in drug formulation, playing crucial roles in drug stability, solubility, and bioavailability.

Growing Pharmaceutical Industry : The expanding pharmaceutical sector, driven by increasing healthcare needs and technological advancements, fuels the demand for biopharmaceutical excipients.

Rising Demand for Biologics : With the surge in biologics development, there's a parallel need for excipients compatible with these complex molecules, driving innovation in the excipient market.

Regulatory Environment : Stringent regulations regarding excipient safety and efficacy influence market dynamics, shaping product development and manufacturing processes.

Shift towards Novel Drug Delivery Systems : Emerging drug delivery technologies, such as nanoparticles and liposomes, require specialized excipients, fostering market growth and diversification.

Globalization of Pharmaceutical Supply Chains : Increasing globalization in the pharmaceutical industry expands the market reach for excipient manufacturers, stimulating competition and innovation.

Focus on Patient-Centric Formulations : Growing emphasis on patient convenience and compliance drives the demand for excipients suitable for various dosage forms, including orally disintegrating tablets and modified-release formulations.

Technological Advancements : Advancements in excipient manufacturing processes and formulation techniques enhance product efficacy and safety, driving market expansion.

Growing Biopharmaceutical Outsourcing : Pharmaceutical companies increasingly outsource manufacturing activities, creating opportunities for excipient suppliers to offer specialized solutions and services.

Market Consolidation and Mergers : Mergers and acquisitions among excipient manufacturers reshape the competitive landscape, influencing market dynamics and product innovation.

Emerging Markets : Rapid expansion of healthcare infrastructure in emerging markets creates opportunities for excipient manufacturers to cater to growing pharmaceutical demands in these regions.

Sustainability Initiatives : Increasing focus on sustainable manufacturing practices prompts excipient suppliers to develop eco-friendly alternatives, aligning with market trends and regulatory requirements.

Cost Pressures : Intense cost pressures in the pharmaceutical industry drive the demand for cost-effective excipients without compromising quality or performance, shaping market preferences.

Drug Patent Expirations : Patent expirations for blockbuster drugs create opportunities for generic manufacturers, driving demand for excipients in generic drug formulations.

Collaborative Research Initiatives : Collaborative research efforts between excipient manufacturers, pharmaceutical companies, and academic institutions drive innovation in excipient development, addressing evolving market needs.

Market Fragmentation : The biopharmaceutical excipients market comprises a diverse range of players, from multinational corporations to niche suppliers, contributing to market fragmentation and competitive dynamics.

Supply Chain Disruptions : Vulnerabilities in global supply chains, as seen during the COVID-19 pandemic, highlight the importance of supply chain resilience and localized manufacturing in the excipient market.

Market Segmentation : Segmentation based on excipient type, functionality, and application allows manufacturers to target specific market niches and optimize product offerings.

Quality Standards and Compliance : Adherence to stringent quality standards and regulatory compliance is imperative for excipient manufacturers to ensure product safety and efficacy, influencing market competitiveness.

Future Outlook : The biopharmaceutical excipients market is poised for continued growth, driven by technological advancements, regulatory changes, and evolving healthcare needs, presenting opportunities for innovation and market expansion.

Biopharmaceutical Excipients Market Size Graph
Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Biopharmaceutical Excipients Market by 2035?

<p>The projected market valuation of the Biopharmaceutical Excipients Market is expected to reach 12.4 USD Billion by 2035.</p>

What was the market valuation of the Biopharmaceutical Excipients Market in 2024?

<p>The overall market valuation of the Biopharmaceutical Excipients Market was 7.18 USD Billion in 2024.</p>

What is the expected CAGR for the Biopharmaceutical Excipients Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Biopharmaceutical Excipients Market during the forecast period 2025 - 2035 is 5.09%.</p>

Which application segment is projected to have the highest valuation by 2035?

<p>The Injectable Formulations segment is projected to reach a valuation of 2.5 USD Billion by 2035.</p>

What are the key types of excipients in the Biopharmaceutical Excipients Market?

<p>Key types of excipients include Binders, Disintegrants, Lubricants, Preservatives, and Stabilizers.</p>

Which end-use segment is expected to dominate the market by 2035?

<p>The Pharmaceutical Companies segment is expected to dominate the market, projected to reach 6.0 USD Billion by 2035.</p>

Who are the leading players in the Biopharmaceutical Excipients Market?

<p>Key players in the market include BASF SE, Evonik Industries AG, Dow Inc., and Merck KGaA.</p>

What is the projected valuation for the Active Excipients segment by 2035?

<p>The Active Excipients segment is projected to reach a valuation of 4.6 USD Billion by 2035.</p>

How does the market for Multi-functional Excipients compare to Functional Excipients by 2035?

<p>By 2035, the Multi-functional Excipients segment is expected to reach 3.5 USD Billion, while Functional Excipients may reach 2.5 USD Billion.</p>

What is the anticipated growth trend for the Cell and Gene Therapy segment by 2035?

<p>The Cell and Gene Therapy segment is anticipated to grow to 3.1 USD Billion by 2035.</p>

Market Summary

As per MRFR analysis, the Biopharmaceutical Excipients Market size was valued at USD 7.18 Billion in 2024. The market is projected to grow from USD 7.545 Billion in 2025 to USD 12.4 Billion by 2035, exhibiting a CAGR of 5.0% during the forecast period 2025–2035.North America dominated the Biopharmaceutical Excipients Market with the largest revenue share of 44.57% in 2024.

Key Market Trends & Highlights

The Biopharmaceutical Excipients Market is poised for substantial growth driven by innovation and sustainability initiatives.

  • North America remains the largest market for biopharmaceutical excipients, reflecting a robust demand for advanced drug formulations. Asia-Pacific is emerging as the fastest-growing region, propelled by increasing investments in biopharmaceutical research and development. Injectable formulations dominate the market, while oral formulations are witnessing rapid growth due to their convenience and patient compliance. The rising demand for biopharmaceuticals and innovations in drug delivery systems are key drivers influencing market expansion.

Market Size & Forecast

2024 Market Size 7.18 (USD Billion)
2035 Market Size 12.4 (USD Billion)
CAGR (2025 - 2035) 5.09%
Largest Regional Market Share in 2024 North America

Major Players

BASF SE (DE), Evonik Industries AG (DE), Dow Inc. (US), FMC Corporation (US), JRS Pharma (DE), Ashland Global Holdings Inc. (US),  Merck KGaA (DE), Sodium Hyaluronate (JP), <a href="https://www.crodapharma.com/en-gb/drug-delivery-solutions/explore-by-product/super-refined-excipients">Croda International Plc </a>(GB)

Market Trends

The Biopharmaceutical Excipients Market is currently experiencing a dynamic evolution, driven by the increasing demand for biopharmaceutical products. This growth is largely attributed to advancements in biotechnology and the rising prevalence of chronic diseases, which necessitate innovative therapeutic solutions.

 As the industry progresses, the role of excipients becomes more critical, serving not only as inactive ingredients but also as facilitators of drug delivery and stability. The market landscape is characterized by a diverse range of excipients, including stabilizers, preservatives, and solubilizers, each tailored to enhance the efficacy of biopharmaceutical formulations.

 Moreover, the Biopharmaceutical Excipients Market is witnessing a shift towards more sustainable and natural excipients, reflecting a broader trend in the pharmaceutical industry towards environmentally friendly practices. Regulatory bodies are increasingly emphasizing the importance of excipient quality and safety, which further influences market dynamics.

As manufacturers strive to meet these evolving standards, the focus on research and development intensifies, potentially leading to the introduction of novel excipients that could redefine formulation strategies. Overall, the market appears poised for continued growth, driven by innovation and a commitment to improving patient outcomes.

Sustainability in Excipients

There is a noticeable trend towards the adoption of sustainable excipients within the Biopharmaceutical Excipients Market. This shift is influenced by growing environmental concerns and the demand for greener pharmaceutical practices. Manufacturers are exploring natural sources and biodegradable materials, which may enhance the appeal of biopharmaceutical products while aligning with global sustainability goals.

Regulatory Compliance and Quality Assurance

The emphasis on regulatory compliance and quality assurance is becoming increasingly pronounced in the Biopharmaceutical Excipients Market. Stricter guidelines from regulatory authorities necessitate that manufacturers prioritize the safety and efficacy of excipients. This trend may lead to enhanced quality control measures and a focus on transparency in sourcing and production processes.

Technological Advancements in Formulation

Technological advancements are significantly shaping the Biopharmaceutical Excipients Market. Innovations in formulation techniques, such as nanotechnology and advanced delivery systems, are likely to enhance the performance of excipients. These developments may facilitate the creation of more effective biopharmaceutical products, thereby addressing complex therapeutic challenges.

Biopharmaceutical Excipients Market Market Drivers

Regulatory Pressures and Compliance

Regulatory frameworks governing biopharmaceuticals are becoming increasingly stringent, impacting the Biopharmaceutical Excipients Market. Compliance with these regulations necessitates the use of high-quality excipients that meet safety and efficacy standards.
 
As regulatory bodies emphasize the importance of quality assurance, manufacturers are compelled to invest in excipients that not only comply with these regulations but also enhance the overall quality of biopharmaceutical products. This trend is likely to drive innovation and growth within the excipients market.

Innovations in Drug Delivery Systems

Advancements in drug delivery technologies are significantly influencing the Biopharmaceutical Excipients Market. Innovations such as nanotechnology and targeted delivery systems are enhancing the effectiveness of biopharmaceuticals.
 
These technologies require specialized excipients that can improve solubility, stability, and bioavailability of active pharmaceutical ingredients. The market for excipients tailored for these advanced delivery systems is expected to witness substantial growth, as pharmaceutical companies increasingly seek to optimize their formulations to meet patient needs and regulatory standards.

Rising Demand for Biopharmaceuticals

The increasing prevalence of chronic diseases and the aging population are driving the demand for biopharmaceuticals. This trend is expected to bolster the Biopharmaceutical Excipients Market, as excipients play a crucial role in the formulation and stability of biopharmaceutical products.
 
According to recent estimates, the biopharmaceutical sector is projected to grow at a compound annual growth rate of over 8% in the coming years. This growth is likely to create a corresponding demand for excipients that enhance drug delivery and efficacy, thereby expanding the market for biopharmaceutical excipients.

Increased Focus on Personalized Medicine

The shift towards personalized medicine is reshaping the Biopharmaceutical Excipients Market. As therapies become more tailored to individual patient profiles, the demand for excipients that can accommodate diverse formulations is likely to rise.
 
This trend is supported by the growing number of biopharmaceuticals entering the market, which often require unique excipient profiles to ensure efficacy and safety. The market for excipients that facilitate personalized therapies is anticipated to expand, reflecting the broader movement towards customized healthcare solutions.

Sustainability Initiatives in Pharmaceutical Manufacturing

The growing emphasis on sustainability in pharmaceutical manufacturing is influencing the Biopharmaceutical Excipients Market. Companies are increasingly seeking excipients derived from renewable sources or those that minimize environmental impact.
 
This shift towards sustainable practices is not only driven by regulatory requirements but also by consumer demand for environmentally friendly products. As a result, the market for sustainable excipients is expected to grow, reflecting a broader commitment to sustainability within the biopharmaceutical sector.

Market Segment Insights

By Application: Injectable Formulations (Largest) vs. Oral Formulations (Fastest-Growing)

In the Biopharmaceutical Excipients Market, the application segment showcases a diverse landscape, with Injectable Formulations holding the largest share largely due to their critical role in vaccine delivery and biologics. Following them are Oral Formulations, which are gaining traction as patient preference shifts towards more convenient administration methods. In contrast, Topical and Transdermal Formulations, while significant, remain niche, primarily catered to specific therapeutic areas. Cell and Gene Therapy applications are emerging, indicating a dynamic shift towards innovative treatment modalities.

Formulations: Injectable (Dominant) vs. Oral (Emerging)

Injectable Formulations are currently the dominant player in the market share, largely due to their essential application in delivering therapeutic agents effectively and their pivotal role in vaccine development. These formulations require excipients that enhance solubility and stability, making them crucial for high-performance delivery systems. In comparison, Oral Formulations are emerging with rapid growth driven by patient convenience and advancements in drug delivery technologies. This segment relies on excipients that ensure bioavailability and suitable release profiles, catering to the demand for more user-friendly and efficient therapeutic options.

By Type: Binders (Largest) vs. Disintegrants (Fastest-Growing)

In the Biopharmaceutical Excipients Market, the 'Binders' segment holds a significant share due to its critical role in ensuring the mechanical strength and stability of tablets and other dosage forms. Binders are essential for granulation processes, thus maintaining the integrity of drug formulations. On the other hand, 'Disintegrants' are gaining increasing traction as they facilitate the rapid breakdown of tablets into active forms, which is critical for the bioavailability of oral medications. This rising trend is reflective of the growing demand for efficient drug delivery systems, aiding in the overall market dynamics. Growth trends within the segment are propelled by advancements in formulation technologies and the increasing need for patient-centric drug delivery solutions. The demand for faster-acting medications has amplified the focus on excipients that aid in disintegration and dissolution. Additionally, the rise in the prevalence of chronic diseases has necessitated the development of innovative excipient solutions, thus creating a robust growth environment for Disintegrants in particular, spotlighting them as the fastest-growing segment in the market.

Binders (Dominant) vs. Disintegrants (Emerging)

Binders are characterized by their vital role in holding various ingredients together, providing structural integrity to solid dosage forms. This segment is dominated by a few established players who offer a range of synthetic and natural binders that cater to various biopharmaceutical applications. Binders ensure that drug formulations can withstand processing and handling. Conversely, Disintegrants, identified as emerging ingredients, are gaining popularity for their ability to enhance the dissolution rate of <a title="active pharmaceutical ingredients" href="https://www.marketresearchfuture.com/reports/active-pharmaceutical-ingredients-market-1385" target="_blank" rel="noopener">active pharmaceutical ingredients</a>, particularly in oral dosage forms. As formulators increasingly prioritize bioavailability, the demand for effective Disintegrants is expected to rise. This segment is marked by innovation, with manufacturers exploring new materials and technologies to improve disintegration properties, thereby carving out a significant niche and fast-paced growth in the market.

By Functionality: Functional Excipients (Largest) vs. Multi-functional Excipients (Fastest-Growing)

In the Biopharmaceutical Excipients Market, the segment of functional excipients holds the largest share due to their critical roles in improving the stability and bioavailability of biopharmaceuticals. These excipients are specifically designed to enhance the functionality of the active pharmaceutical ingredients, contributing significantly to the efficacy and performance of drug formulations. On the other hand, multi-functional excipients have emerged rapidly, driven by the increasing need for cost-effective solutions that can serve multiple purposes within drug formulation. Their versatility is appealing to formulators looking to simplify processes and reduce the number of components in a formulation, leading to their designation as the fastest-growing segment.

Functional Excipients (Dominant) vs. Active Excipients (Emerging)

Functional excipients are renowned for their dominant role in enhancing the stability, release profiles, and overall effectiveness of biopharmaceutical products. They include stabilizers, emulsifiers, and solubilizers, which are essential in ensuring the reliability and performance of therapeutic applications. In contrast, active excipients, although emerging, are increasingly recognized for their potential to contribute to the pharmacological action of the formulations. As the industry evolves, active excipients are being investigated for their unique properties that allow them to influence drug release and absorption, thus presenting new opportunities in drug design while maintaining therapeutic efficacy.

By End-use: Pharmaceutical Companies (Largest) vs. Contract Manufacturing Organizations (Fastest-Growing)

In the Biopharmaceutical Excipients Market, pharmaceutical companies dominate the landscape, holding the largest market share due to their established presence and extensive product portfolios. These companies leverage excipients to enhance drug formulations, resulting in higher efficacy and patient compliance. Meanwhile, contract manufacturing organizations (CMOs) are rapidly gaining traction, driven by the increasing outsourcing of drug development and production processes, allowing pharmaceutical companies to focus on core competencies while benefiting from the specialized services of CMOs.

Pharmaceutical Companies (Dominant) vs. Contract Manufacturing Organizations (Emerging)

Pharmaceutical companies play a dominant role in the market share, characterized by their significant investments in R&amp;D and a robust pipeline of innovative drug formulations. Their extensive experience in drug development allows them to tailor excipients to meet specific therapeutic needs. In contrast, contract manufacturing organizations are emerging as vital players in the market, providing specialized manufacturing services that cater to a diverse range of biopharmaceutical products. They are increasingly favored for their flexibility, scalability, and ability to comply with stringent regulatory standards, which enables them to adapt quickly to the evolving demands of pharmaceutical clients.

Get more detailed insights about Biopharmaceutical Excipients Market Research Report-Forecast to 2035

Regional Insights

North America accounted for the largest share of the Biopharmaceutical Excipients Market size, reaching USD 3.2 billion in 2024, reflecting its advanced infrastructure and extensive Research and Development efforts, which drive innovation and growth.

Following closely was Europe, valued at 1.8 USD Billion in the same year, benefitting from strong regulatory frameworks and a growing focus on personalized medicine. The Asia Pacific region held a value of 1.85 USD Billion, driven by increasing investments in healthcare and rising demand for biologics.

South America, although smaller in the landscape, had a valuation of 0.5 USD Billion, indicating potential growth opportunities with ongoing enhancements in healthcare frameworks. The Middle East and Africa, valued at 0.13 USD Billion, represented the emerging facet of the market, gradually expanding with a focus on improving healthcare access.

Overall, the Biopharmaceutical Excipients Market segmentation reflected robust growth patterns influenced by regional healthcare needs, regulatory considerations, and innovation, presenting numerous opportunities for stakeholders in the industry.

Key Players and Competitive Insights

The Biopharmaceutical Excipients Market has increasingly become a focal point for companies engaged in the pharmaceutical sector, driven by the growing demand for innovative drug formulations and biologics. As the biopharmaceutical industry continues to expand, the need for excipients that are functional and compliant with rigorous regulatory standards has led to intense competition among manufacturers.
 
Companies are focusing on enhancing product portfolios, improving manufacturing processes, and complying with emerging regulatory requirements, which plays a significant role in shaping market dynamics. The competitive landscape is marked by mergers, acquisitions, and strategic partnerships, ensuring that companies not only maintain their market share but also effectively address the evolving needs of End-users. Technological advancements alongside a focus on sustainability are driving innovations in excipient formulations, providing essential support to the biopharmaceutical drug development process. Kraft Chemical Company has established itself as a formidable player in the Biopharmaceutical Excipients Market through its dedication to quality and innovative solutions.
 
The company’s strengths lie in its extensive research and development capabilities, which allow for the formulation of highly effective excipients tailored to meet the intricate needs of biopharmaceutical applications. Kraft Chemical's commitment to customer satisfaction and regulatory compliance ensures that it provides excipients that enhance the stability and efficacy of biopharmaceutical products. Furthermore, the company leverages its industry expertise and maintains strong relationships with a diverse range of clients, which solidifies its presence in the global market.
 
The strategic focus on developing specialized excipients for specific applications also empowers Kraft Chemical to differentiate itself and compete effectively against other players in the market. Clariant is another key entity in the Biopharmaceutical Excipients Market, recognized for its comprehensive range of products and services. The company offers an array of excipients that play critical roles in enhancing the performance of drug formulations, including functional additives, stabilizers, and release agents. Clariant's global presence is amplified by its established network of manufacturing facilities and sales offices, enabling efficient distribution of its products worldwide.
 
The company emphasizes innovation and sustainability, focusing on developing green and bio-based excipients in response to industry trends towards environmentally friendly practices. Clariant’s strengths are furthered through strategic mergers and acquisitions that have expanded its product offerings and technological capabilities, positioning the company favorably within the competitive landscape. By continuously adapting to market demands and investing in research and development, Clariant has solidified its reputation as a leading provider of biopharmaceutical excipients on a global scale.

Key Companies in the Biopharmaceutical Excipients Market include

Industry Developments

In order to increase India's independence in advanced drug formulation components, Nitika Pharmaceutical Specialties Pvt Ltd in Nagpur received financial support in June 2025 from the Department of Science and Technology's India Technology Development Board (TDB) to establish a commercial-scale facility to manufacture 14 complex biopharmaceutical excipients.

To bolster its expertise in pharmaceutical excipients, particularly for biopharmaceutical applications, Roquette finalized the purchase of Qualicaps in July 2023.

In order to facilitate the development of a new SN-38-based treatment for colorectal cancer, Lubrizol Corporation and Welton Pharma signed a licensing agreement in June 2023 for the use of its Apisolex excipient. In order to provide a steady supply of essential excipients for mRNA vaccines and nucleic acid therapies, Evonik stated in March 2023 that it was expanding its facilities in Lafayette, USA.

Three high-purity VitiPure excipients were released by Clariant in October 2023 to improve the stability and solubility of APIs, especially in mRNA and biologic formulations.

Leading international suppliers like Merck, BASF, Avantor, Evonik, Roquette Frères, and Associated British Foods are seeking strategic licensing, acquisitions, and partnerships to expand portfolios, increase R&D, and improve distribution in the biopharmaceutical excipient industry, according to a report published in August 2024 by ResearchAndMarkets.

Future Outlook

Biopharmaceutical Excipients Market Future Outlook

The Biopharmaceutical Excipients Market is projected to grow at a 5.09% CAGR from 2025 to 2035, driven by increasing demand for biologics and advanced drug formulations.

New opportunities lie in:

  • <p>Development of multifunctional excipients for enhanced <a href="https://www.marketresearchfuture.com/reports/drug-delivery-system-market-43638">drug delivery systems.</a> Investment in sustainable excipient production technologies to meet regulatory standards. Expansion into emerging markets with tailored excipient solutions for local manufacturers.</p>

By 2035, the market is expected to achieve robust growth, reflecting evolving industry needs.

Market Segmentation

Biopharmaceutical Excipients Market Type Outlook

  • Binders
  • Disintegrants
  • Lubricants
  • Preservatives
  • Stabilizers

Biopharmaceutical Excipients Market End-use Outlook

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Research Institutes

Biopharmaceutical Excipients Market Application Outlook

  • Injectable Formulations
  • Oral Formulations
  • Topical Formulations
  • Transdermal Formulations
  • Cell and Gene Therapy

Biopharmaceutical Excipients Market Functionality Outlook

  • Functional Excipients
  • Multi-functional Excipients
  • Inert Excipients
  • Active Excipients

Report Scope

MARKET SIZE 2024 7.18(USD Billion)
MARKET SIZE 2025 7.545(USD Billion)
MARKET SIZE 2035 12.4(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.09% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled BASF SE (DE), Evonik Industries AG (DE), Dow Inc. (US), FMC Corporation (US), JRS Pharma (DE), Ashland Global Holdings Inc. (US), Merck KGaA (DE), Sodium Hyaluronate (JP), Croda International Plc (GB)
Segments Covered Application, Type, Functionality, End-use, Regional
Key Market Opportunities Advancements in personalized medicine drive demand for innovative excipients in the Biopharmaceutical Excipients Market.
Key Market Dynamics Rising demand for biopharmaceutical excipients driven by technological advancements and regulatory changes in drug formulation.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Biopharmaceutical Excipients Market by 2035?

<p>The projected market valuation of the Biopharmaceutical Excipients Market is expected to reach 12.4 USD Billion by 2035.</p>

What was the market valuation of the Biopharmaceutical Excipients Market in 2024?

<p>The overall market valuation of the Biopharmaceutical Excipients Market was 7.18 USD Billion in 2024.</p>

What is the expected CAGR for the Biopharmaceutical Excipients Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Biopharmaceutical Excipients Market during the forecast period 2025 - 2035 is 5.09%.</p>

Which application segment is projected to have the highest valuation by 2035?

<p>The Injectable Formulations segment is projected to reach a valuation of 2.5 USD Billion by 2035.</p>

What are the key types of excipients in the Biopharmaceutical Excipients Market?

<p>Key types of excipients include Binders, Disintegrants, Lubricants, Preservatives, and Stabilizers.</p>

Which end-use segment is expected to dominate the market by 2035?

<p>The Pharmaceutical Companies segment is expected to dominate the market, projected to reach 6.0 USD Billion by 2035.</p>

Who are the leading players in the Biopharmaceutical Excipients Market?

<p>Key players in the market include BASF SE, Evonik Industries AG, Dow Inc., and Merck KGaA.</p>

What is the projected valuation for the Active Excipients segment by 2035?

<p>The Active Excipients segment is projected to reach a valuation of 4.6 USD Billion by 2035.</p>

How does the market for Multi-functional Excipients compare to Functional Excipients by 2035?

<p>By 2035, the Multi-functional Excipients segment is expected to reach 3.5 USD Billion, while Functional Excipients may reach 2.5 USD Billion.</p>

What is the anticipated growth trend for the Cell and Gene Therapy segment by 2035?

<p>The Cell and Gene Therapy segment is anticipated to grow to 3.1 USD Billion by 2035.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. EXECUTIVE SUMMARY | |
      1. Market Overview | |
      2. Key Findings | |
      3. Market Segmentation | |
      4. Competitive Landscape | |
      5. Challenges and Opportunities | |
      6. Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. MARKET INTRODUCTION | |
      1. Definition | |
      2. Scope of the study | | |
    2. RESEARCH METHODOLOGY | |
      1. Overview | |
      2. Data Mining | |
      3. Secondary Research | |
      4. Primary Research | | |
      5. Forecasting Model | |
      6. Market Size Estimation | | |
      7. Data Triangulation | |
      8. Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. MARKET DYNAMICS | |
      1. Overview | |
      2. Drivers | |
      3. Restraints | |
      4. Opportunities |
    2. MARKET FACTOR ANALYSIS | |
      1. Value chain Analysis | |
      2. Porter's Five Forces Analysis | | |
      3. COVID-19 Impact Analysis | | |
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. Healthcare, BY Application (USD Billion) | |
      1. Injectable Formulations | |
      2. Oral Formulations | |
      3. Topical Formulations | |
      4. Transdermal Formulations | |
      5. Cell and Gene Therapy |
    2. Healthcare, BY Type (USD Billion) | |
      1. Binders | |
      2. Disintegrants | |
      3. Lubricants | |
      4. Preservatives | |
      5. Stabilizers |
    3. Healthcare, BY Functionality (USD Billion) | |
      1. Functional Excipients | |
      2. Multi-functional Excipients | |
      3. Inert Excipients | |
      4. Active Excipients |
    4. Healthcare, BY End-use (USD Billion) | |
      1. Pharmaceutical Companies | |
      2. Contract Manufacturing Organizations | |
      3. Research Institutes |
    5. Healthcare, BY Region (USD Billion) | |
      1. North America | | |
      2. Europe | | |
      3. APAC | | |
      4. South America | | |
      5. MEA | | |
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. Competitive Landscape | |
      1. Overview | |
      2. Competitive Analysis | |
      3. Market share Analysis | |
      4. Major Growth Strategy in the Healthcare | |
      5. Competitive Benchmarking | |
      6. Leading Players in Terms of Number of Developments in the Healthcare | |
      7. Key developments and growth strategies | | |
      8. Major Players Financial Matrix | | |
    2. Company Profiles | |
      1. BASF SE (DE) | | |
      2. Evonik Industries AG (DE) | | |
      3. Dow Inc. (US) | | |
      4. FMC Corporation (US) | | |
      5. JRS Pharma (DE) | | |
      6. Ashland Global Holdings Inc. (US) | | |
      7. Merck KGaA (DE) | | |
      8. Sodium Hyaluronate (JP) | | |
      9. Croda International Plc (GB) | | |
    3. Appendix | |
      1. References | |
      2. Related Reports 6 LIST OF FIGURES |
    4. MARKET SYNOPSIS |
    5. NORTH AMERICA MARKET ANALYSIS |
    6. US MARKET ANALYSIS BY APPLICATION |
    7. US MARKET ANALYSIS BY TYPE |
    8. US MARKET ANALYSIS BY FUNCTIONALITY |
    9. US MARKET ANALYSIS BY END-USE |
    10. CANADA MARKET ANALYSIS BY APPLICATION |
    11. CANADA MARKET ANALYSIS BY TYPE |
    12. CANADA MARKET ANALYSIS BY FUNCTIONALITY |
    13. CANADA MARKET ANALYSIS BY END-USE |
    14. EUROPE MARKET ANALYSIS |
    15. GERMANY MARKET ANALYSIS BY APPLICATION |
    16. GERMANY MARKET ANALYSIS BY TYPE |
    17. GERMANY MARKET ANALYSIS BY FUNCTIONALITY |
    18. GERMANY MARKET ANALYSIS BY END-USE |
    19. UK MARKET ANALYSIS BY APPLICATION |
    20. UK MARKET ANALYSIS BY TYPE |
    21. UK MARKET ANALYSIS BY FUNCTIONALITY |
    22. UK MARKET ANALYSIS BY END-USE |
    23. FRANCE MARKET ANALYSIS BY APPLICATION |
    24. FRANCE MARKET ANALYSIS BY TYPE |
    25. FRANCE MARKET ANALYSIS BY FUNCTIONALITY |
    26. FRANCE MARKET ANALYSIS BY END-USE |
    27. RUSSIA MARKET ANALYSIS BY APPLICATION |
    28. RUSSIA MARKET ANALYSIS BY TYPE |
    29. RUSSIA MARKET ANALYSIS BY FUNCTIONALITY |
    30. RUSSIA MARKET ANALYSIS BY END-USE |
    31. ITALY MARKET ANALYSIS BY APPLICATION |
    32. ITALY MARKET ANALYSIS BY TYPE |
    33. ITALY MARKET ANALYSIS BY FUNCTIONALITY |
    34. ITALY MARKET ANALYSIS BY END-USE |
    35. SPAIN MARKET ANALYSIS BY APPLICATION |
    36. SPAIN MARKET ANALYSIS BY TYPE |
    37. SPAIN MARKET ANALYSIS BY FUNCTIONALITY |
    38. SPAIN MARKET ANALYSIS BY END-USE |
    39. REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    40. REST OF EUROPE MARKET ANALYSIS BY TYPE |
    41. REST OF EUROPE MARKET ANALYSIS BY FUNCTIONALITY |
    42. REST OF EUROPE MARKET ANALYSIS BY END-USE |
    43. APAC MARKET ANALYSIS |
    44. CHINA MARKET ANALYSIS BY APPLICATION |
    45. CHINA MARKET ANALYSIS BY TYPE |
    46. CHINA MARKET ANALYSIS BY FUNCTIONALITY |
    47. CHINA MARKET ANALYSIS BY END-USE |
    48. INDIA MARKET ANALYSIS BY APPLICATION |
    49. INDIA MARKET ANALYSIS BY TYPE |
    50. INDIA MARKET ANALYSIS BY FUNCTIONALITY |
    51. INDIA MARKET ANALYSIS BY END-USE |
    52. JAPAN MARKET ANALYSIS BY APPLICATION |
    53. JAPAN MARKET ANALYSIS BY TYPE |
    54. JAPAN MARKET ANALYSIS BY FUNCTIONALITY |
    55. JAPAN MARKET ANALYSIS BY END-USE |
    56. SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    57. SOUTH KOREA MARKET ANALYSIS BY TYPE |
    58. SOUTH KOREA MARKET ANALYSIS BY FUNCTIONALITY |
    59. SOUTH KOREA MARKET ANALYSIS BY END-USE |
    60. MALAYSIA MARKET ANALYSIS BY APPLICATION |
    61. MALAYSIA MARKET ANALYSIS BY TYPE |
    62. MALAYSIA MARKET ANALYSIS BY FUNCTIONALITY |
    63. MALAYSIA MARKET ANALYSIS BY END-USE |
    64. THAILAND MARKET ANALYSIS BY APPLICATION |
    65. THAILAND MARKET ANALYSIS BY TYPE |
    66. THAILAND MARKET ANALYSIS BY FUNCTIONALITY |
    67. THAILAND MARKET ANALYSIS BY END-USE |
    68. INDONESIA MARKET ANALYSIS BY APPLICATION |
    69. INDONESIA MARKET ANALYSIS BY TYPE |
    70. INDONESIA MARKET ANALYSIS BY FUNCTIONALITY |
    71. INDONESIA MARKET ANALYSIS BY END-USE |
    72. REST OF APAC MARKET ANALYSIS BY APPLICATION |
    73. REST OF APAC MARKET ANALYSIS BY TYPE |
    74. REST OF APAC MARKET ANALYSIS BY FUNCTIONALITY |
    75. REST OF APAC MARKET ANALYSIS BY END-USE |
    76. SOUTH AMERICA MARKET ANALYSIS |
    77. BRAZIL MARKET ANALYSIS BY APPLICATION |
    78. BRAZIL MARKET ANALYSIS BY TYPE |
    79. BRAZIL MARKET ANALYSIS BY FUNCTIONALITY |
    80. BRAZIL MARKET ANALYSIS BY END-USE |
    81. MEXICO MARKET ANALYSIS BY APPLICATION |
    82. MEXICO MARKET ANALYSIS BY TYPE |
    83. MEXICO MARKET ANALYSIS BY FUNCTIONALITY |
    84. MEXICO MARKET ANALYSIS BY END-USE |
    85. ARGENTINA MARKET ANALYSIS BY APPLICATION |
    86. ARGENTINA MARKET ANALYSIS BY TYPE |
    87. ARGENTINA MARKET ANALYSIS BY FUNCTIONALITY |
    88. ARGENTINA MARKET ANALYSIS BY END-USE |
    89. REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    90. REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    91. REST OF SOUTH AMERICA MARKET ANALYSIS BY FUNCTIONALITY |
    92. REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USE |
    93. MEA MARKET ANALYSIS |
    94. GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    95. GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    96. GCC COUNTRIES MARKET ANALYSIS BY FUNCTIONALITY |
    97. GCC COUNTRIES MARKET ANALYSIS BY END-USE |
    98. SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    99. SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    100. SOUTH AFRICA MARKET ANALYSIS BY FUNCTIONALITY |
    101. SOUTH AFRICA MARKET ANALYSIS BY END-USE |
    102. REST OF MEA MARKET ANALYSIS BY APPLICATION |
    103. REST OF MEA MARKET ANALYSIS BY TYPE |
    104. REST OF MEA MARKET ANALYSIS BY FUNCTIONALITY |
    105. REST OF MEA MARKET ANALYSIS BY END-USE |
    106. KEY BUYING CRITERIA OF HEALTHCARE |
    107. RESEARCH PROCESS OF MRFR |
    108. DRO ANALYSIS OF HEALTHCARE |
    109. DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    113. HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    114. HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    115. HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    116. HEALTHCARE, BY FUNCTIONALITY, 2024 (% SHARE) |
    117. HEALTHCARE, BY FUNCTIONALITY, 2024 TO 2035 (USD Billion) |
    118. HEALTHCARE, BY END-USE, 2024 (% SHARE) |
    119. HEALTHCARE, BY END-USE, 2024 TO 2035 (USD Billion) |
    120. BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. LIST OF ASSUMPTIONS | |
      1. |
    122. North America MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    123. US MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    124. Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    125. Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    126. Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    127. UK MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    128. France MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    129. Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    130. Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    131. Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    132. Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    133. APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    134. China MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    135. India MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    136. Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    137. South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    138. Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    139. Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    140. Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    141. Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    142. South America MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    143. Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    144. Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    145. Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    146. Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    147. MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    148. GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    149. South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    150. Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. BY APPLICATION, 2025-2035 (USD Billion) | |
      2. BY TYPE, 2025-2035 (USD Billion) | |
      3. BY FUNCTIONALITY, 2025-2035 (USD Billion) | |
      4. BY END-USE, 2025-2035 (USD Billion) |
    151. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. |
    152. ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Injectable Formulations
  • Oral Formulations
  • Topical Formulations
  • Transdermal Formulations
  • Cell and Gene Therapy

Healthcare By Type (USD Billion, 2025-2035)

  • Binders
  • Disintegrants
  • Lubricants
  • Preservatives
  • Stabilizers

Healthcare By Functionality (USD Billion, 2025-2035)

  • Functional Excipients
  • Multi-functional Excipients
  • Inert Excipients
  • Active Excipients

Healthcare By End-use (USD Billion, 2025-2035)

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Research Institutes
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓
%>